Stocks Health care HROW
NASDAQ · Health careHarrow, Inc. (HROW)
Harrow, Inc. brought in $303.3M of revenue over the twelve months to September 30, 2026, up 21.3% from a year earlier. It posted a net loss of $28.5M. Operating cash flow minus capital spending left $43M of free cash flow in fiscal 2025. At September 30, 2026 it held $75.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Harrow, Inc.
- Net worth
- Harrow, Inc. has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $29.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $272.3M (+36.4% year on year), with a net loss of $5.1M. Over the 12 months to September 30, 2026: revenue $303.3M, net loss $28.5M.
- Cash flow
- In fiscal 2025 operations brought in $43.9M of cash; after $887K of capital spending, free cash flow was $43M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Harrow, Inc.'s next report is expected around February 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Harrow, Inc. does
Harrow, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HROW.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $272.3M | -$5.1M | -$0.14 | $43M |
| 2024 | $199.6M | -$17.5M | -$0.49 | -$23.8M |
| 2023 | $130.2M | -$24.4M | -$0.75 | $2.4M |
| 2022 | $88.6M | -$14.1M | -$0.51 | -$892K |
| 2021 | $72.5M | -$18M | -$0.69 | $3.3M |
| 2020 | $48.9M | -$3.4M | -$0.13 | -$2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HROW ranks in Health care
Latest SEC filings
What Harrow, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 39% to $99.3M versus the same quarter last year; diluted EPS $0.25 versus $0.03.
- November 9, 2026
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 5, 2026Acquisition or sale completed8-KHarrow completed its acquisition of worldwide rights to the dry eye nasal spray TYRVAYA from Viatris, excluding Japan.
- September 4, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $70.7M versus the same quarter last year; diluted EPS -$0.46 versus $0.13.
- August 10, 2026
- August 6, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
What is HROW worth? A DCF from its reported cash flow
Insider trades
What the people running Harrow, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $450K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 14, 2026 | Shojaei AmirCHIEF SCIENTIFIC OFFICER | Exercised options | 11,250 | $404.6K |
| August 14, 2026 | Shojaei AmirCHIEF SCIENTIFIC OFFICER | Sold | 11,250 | $450K |
| May 18, 2026 | Silvernail Lauren PDirector | Bought | 1,000 | $31K |
| May 18, 2026 | Graves Adrienne LDirector | Bought | 1,000 | $31.1K |
| May 14, 2026 | Boll Andrew R.PRESIDENT AND CFO | Bought | 3,500 | $104.7K |
| May 14, 2026 | Baum Mark LCHIEF EXECUTIVE OFFICER, Director | Bought | 10,000 | $302K |
| March 4, 2026 | Opaleye Management Inc.10% owner | Soldindirect | 134,000 | $5.3M |
| March 4, 2026 | Opaleye Management Inc.10% owner | Soldindirect | 4,263 | $169.1K |
Who owns HROW
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mark L. Baum13D, may seek influence | 10.69% | April 7, 2025 |
| BlackRock, Inc.13G, passive | 7.4% | October 27, 2026 |
| Opaleye Management Inc.13G, passive with 2 related filers | 5.62% | November 6, 2026 |
| Daniel Kaufman13G, passive | 5.04% | March 11, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 223 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 2,740,117 | +187,358 |
| Opaleye Management Inc. | 2,400,000 | -432,230 |
| Private Capital Management, LLC | 1,598,770 | +36,770 |
| Vanguard Capital Management LLC | 1,417,212 | +14,156 |
| Deep Track Capital, LP | 969,000 | new |
| State Street Corp | 939,888 | +84,841 |
| Geode Capital Management, LLC | 905,560 | +53,526 |
| Bamco Inc | 809,350 | new |
| Dimensional Fund Advisors LP | 667,036 | +87,516 |
| Jupiter Topco LLC | 579,127 | new |
| Divisadero Street Capital Management, LP | 439,155 | new |
| Rice Hall James & Associates, LLC | 387,545 | +19,368 |
| Marshall Wace, Llp | 369,435 | -275,483 |
| Citadel Advisors LLC | 359,874 | +138,616 |
| Northern Trust Corp | 323,206 | +26,341 |
| Schonfeld Strategic Advisors LLC | 319,625 | new |
| Vanguard Portfolio Management LLC | 318,610 | +29,735 |
| Charles Schwab Investment Management Inc | 273,696 | +3,160 |
| Vanguard Fiduciary Trust Co | 235,418 | +7,797 |
| Westside Investment Management, Inc. | 224,051 | +38,125 |
Insiders
5 insiders reported holding 3,872,237 shares in total, about $106.4M at the last price.
| Holder | Shares |
|---|---|
| Baum Mark LCHIEF EXECUTIVE OFFICER, Director | 2,996,130 |
| Boll Andrew R.PRESIDENT AND CFO | 814,679 |
| Opaleye Management Inc.10% owner | 59,42859,428 held indirectly |
| Silvernail Lauren PDirector | 1,000 |
| Graves Adrienne LDirector | 1,000 |
Questions about HROW
What does Harrow, Inc. do?
Harrow, Inc. is a company in the Health care sector, listed on NASDAQ as HROW. Its shares trade on NASDAQ under the ticker HROW.
What is Harrow, Inc.'s net worth?
Harrow, Inc. has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $29.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Harrow, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $28.5M on revenue of $303.3M.
How much revenue does Harrow, Inc. make?
Over the twelve months to September 30, 2026 Harrow, Inc. reported revenue of $303.3M. That is 21.3% more than a year earlier.
When did Harrow, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Harrow, Inc.'s next earnings report?
Harrow, Inc.'s next report is expected around February 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare HROW with
Follow HROW
Get an email when Harrow, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Harrow, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.